Commercial agreement serves as high-profile third party validation of BullFrog AI’s proprietary capabilities Agreement utilizes BullFrog AI’s ...
Neumora Therapeutics is downgraded from 'Strong Buy' to 'Hold' following KOASTAL-1's failure in the MDD primary endpoint.
A major depressive episode can evolve from seemingly minor "blues" with surprising speed, eventually disrupting your career, ...
Researchers sought to examine sex-related differences in the association between depression subtypes and CVD risk in veterans.
Psychiatrists explain the key neurobiological differences between major depressive disorder and situational sadness, ...
BullFrog AI (BFRG) stock surged 101% after securing a commercial partnership with a top 5 pharma company for depression drug target identification.
The Missouri House is set to approve legislation that could clear the way for the use of psychedelic treatments for certain ...
J&J’s Tamara Werner-Kiechle tells Clinical Trials Arena that the depression landscape needs reframing to ensure optimal ...
Neumora Therapeutics Inc (NMRA) showcases promising clinical developments and a robust cash runway, despite facing setbacks in toxicology studies.
BrainsWay Ltd. (NASDAQ & TASE: BWAY) ('BrainsWay” or the 'Company”), a global leader in advanced noninvasive neurostimulation ...
Monash University and Seaport Therapeutics have developed a new approach to delivering drug molecules that piggybacks onto ...
Each year, 1 in 5 Canadians will experience a mental health issue, and about 50% will have experienced a mental Illness by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results